Exicure Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

$XCUR
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $XCUR alert in real time by email
xcur-20250414
0001698530false00016985302024-08-132024-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 14, 2025
____________________
EXICURE, INC.
(Exact name of Registrant as specified in its charter)
____________________
Delaware001-39011
81-5333008
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

400 Seaport Court, Suite 102
Redwood City, CA 94063
(Address of principal executive offices)


Registrant’s telephone number, including area code: (847) 673-1700
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareXCURThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
 



Item 4.01 Changes in Registrant's Certifying Accountant

Based on information provided by Marcum LLP (“Marcum”), the independent registered public accounting firm of Exicure, Inc. (the “Company”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through April 10, 2025. On April 10, 2025, Marcum resigned as the Company’s independent registered public accounting firm, and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately. The engagement of CBIZ CPAs was approved by the Audit Committee of the Company’s Board of Directors. The services previously provided by Marcum will now be provided by CBIZ CPAs.

Prior to engaging CBIZ CPAs, the Company did not consult with CBIZ CPAs regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, or (ii) any matter that was either the subject of a disagreement (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K and the related instructions).

The reports of Marcum regarding the Company’s consolidated financial statements for the fiscal years ended December 31, 2024 and 2023, did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except for the inclusion of an explanatory paragraph in the audit reports for the fiscal years ended December 31, 2024 and 2023 as to the Company’s ability to continue as a going concern.

During the years ended December 31, 2024 and 2023, and through April 10, 2025, the date of Marcum’s resignation, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to such disagreement in its reports and (b) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions), except that, as reported in the Company’s 10-Q for the fiscal period ended June 30, 2023, as of June 30, 2023, the Company determined there was a material weakness in its internal control over financial reporting due to a deficiency in its controls over financial reporting. As previously reported, this material weakness has not yet been remediated, did not result in any identified misstatement, and there were no changes to previously reported financial results.

The Company provided Marcum with a copy of this Current Report on Form 8-K prior to its filing with the U.S. Securities and Exchange Commission (the “SEC”) and requested that Marcum furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter, dated April 14, 2025, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.


Item 9.01    Financial Statements and Exhibits.
Exhibit
No.
Description
16.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document).




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 14, 2025
EXICURE, INC.
By:/s/ Andy Yoo
Andy Yoo
Chief Executive Officer


Get the next $XCUR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XCUR

DatePrice TargetRatingAnalyst
12/13/2021$2.25 → $0.40Buy → Neutral
Chardan Capital Markets
11/23/2021$7.00 → $2.25Buy
Chardan Capital
More analyst ratings

$XCUR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

    Exicure, Inc. (NASDAQ:XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule CXCR4 inhibitor, for the mobilization of stem cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) (NCT05561751). The study is an open-label, multi-center trial evaluating the safety and efficacy of GPC-100 and propranolol in combination with G-CSF. Data from an interim analysis of 10 patients were previously presented at the 2024 American Society of Hematology (ASH) Annual Meeting. Preliminary results are encouraging, with 100% of patients

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

    Exicure, Inc. (NASDAQ:XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that GPC-100, when paired with modern AML treatment regimens, can further improve outcomes in this high unmet need clinical indication. A Phase 1 chemosensitization study involving 15 patients with relapsed or refractory AML was previously conducted by Taigen, the original developer of GPC-100. In that study, GPC-100 was combined with fludarabine and cytarabine to evaluate safety and preliminary efficacy. Preclinical data published by Dr. Pam Be

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Exicure, Inc. Reports Full Year 2024 Financial Results

    Exicure, Inc. (NASDAQ:XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. 2024 Financial Results Cash Posit

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$XCUR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$XCUR
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$XCUR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$XCUR
SEC Filings

See more

$XCUR
Leadership Updates

Live Leadership Updates

See more
  • Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

    Exicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17, 2024 (the "Change of Control"), the stockholders of the Company approved a second investment of $8.7 million from HiTron Systems Inc. ("HiTron"), a publicly listed company (KOSPI) in South Korea. This investment is expected to close within a few days depending on regulatory approvals. Also, on December 19, 2024, the Board of Directors (the "Board") of the Company changed the authorized number of directors comprising the Board to nine directors and appointed four new directors

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

    Exicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of August 21, 2023, Paul Kang, a Class III director, was appointed as Chief Executive Officer of the Company and Jiyoung Hwang, a Class I director, was appointed as Chief Financial Officer of the Company. Mr. Kang and Ms. Hwang succeed Mr. Jung-Sang (Michael) Kim, who stepped down as Chief Executive Officer and Chief Financial Officer last Friday. Additionally, effective as of August 21, 2023, the Board also approved the appointment of Hyuk Joon (Raymond) Ko as a Class III direct

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

    Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company"), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company's board of directors (the "Board"). The Company today announced that the Board fully supports the strategic vision of Mr. Kim and his ongoing efforts to maximize stockholder v

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$XCUR
Financials

Live finance-specific insights

See more
  • Exicure, Inc. Reports Full Year 2024 Financial Results

    Exicure, Inc. (NASDAQ:XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. 2024 Financial Results Cash Posit

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

    Exicure, Inc. (NASDAQ:XCUR, the ", Company", )) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Equity Financing In an agreement dated November 6, 2024 and executed on November 12, 2024, the Company agreed to sell and issue to HiTron Systems Inc. ("HiTron") 433,333 shares of common stock, par value $0.0001 per share, for $1.3 million, at

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Exicure, Inc. Reports Second Quarter 2024 Financial Results

    Exicure, Inc. (NASDAQ:XCUR, the ", Company", ))), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Second Quarter 2024 Financial Results Cash Position: Cash and cash equivalents were $0.5 million as of June 30, 2024, as compared to $0.8 million as of December 31, 2023. The Company believes that its cash and cash equivalents are insufficie

    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$XCUR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more